In Vitro Diagnostics Quality Control Market worth $1,158 Million by 2025

According to research report the global In Vitro Diagnostics Quality Control Market is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period.

Some of the factors driving the growth of the In Vitro Diagnostics Quality Control Market are increasing number of accredited clinical laboratories, rising demand for external quality assurance support, and growing adoption of third-party quality controls.

Ask For Free PDF Brochure: www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582

The North America is expected to account for the largest share of the global IVD quality control market in 2020, followed by Europe. The large share of the North America can be attributed to the highly developed healthcare system in the US and Canada, and the presence of a large number of leading IVD quality control vendors & national clinical laboratories & hospitals in this region.

Based on applications, the In Vitro Diagnostics Quality Control Market is segmented into clinical chemistry, immunochemistry, hematology, coagulation & hemostasis, microbiology, molecular diagnostics, and other applications (ESR, urine chemistry, immunology, cardiac assessment, and blood morphology). The molecular diagnostics segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the rising prevalence of infectious diseases, cancer, and various genetic disorders; the growing demand for blood screening; and the increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing.

On the basis of type, the quality control products market is segmented into serum/plasma-based controls, whole blood-based controls, urine-based controls, and other controls (controls manufactured from spinal fluid, lipoprotein extracts, and immunoproteins). The serum/plasma-based controls segment is expected to account for the largest market share in 2019. The large share of this segment is mainly attributed to the greater uptake of serum/plasma-based quality controls among laboratories and the widening application areas of these controls for various IVD tests.

The prominent players in this In Vitro Diagnostics Quality Control Market are Bio-Rad Laboratories Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific Inc. (US), Technopath Clinical Diagnostics (Ireland), Bio-Techne Corporation (US), Fortress Diagnostics (UK), SeraCare Life Sciences Inc. (US), SERO AS (Norway), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), and Abbott Laboratories Inc. (US).

Download Report Sample Pages: www.marketsandmarkets.com/requestsampleNew.asp?id=198032582

Bio-Rad Laboratories Inc. (US) was the leading player in the In Vitro Diagnostics Quality Control Market and accounted for the largest share in 2018. The company is a leading provider of clinical diagnostic systems, analytical devices, and instruments. The company has a robust portfolio of quality control products, data management solutions and quality assurance services for hospital laboratories, reference laboratories, transfusion laboratories, and physician office laboratories.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com

Leave a Reply

Your email address will not be published. Required fields are marked *